Medtronic

MDT

Market cap $114B

GALWAY, Ireland, April 13, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Wednesday, June 3, 2026, for its fourth quarter and full fiscal year 2026, which ends on Friday, April 24, 2026. A news release containing summary financial information will be issued at 5:45 a.m.

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced a digital integration between the GE HealthCare bkActiv™ intraoperative ultrasound (iUS) system and the Medtronic Stealth AXiS™ surgical navigation system, which is now commercially available to provide real-time advanced imaging during cranial procedures to complement surgical planning and navigation workflows. This integration builds on an existing strategic alliance between the companies to accelerate next-generation technology innovati.

In the latest trading session, Medtronic (MDT) closed at $88.65, marking a +2.58% move from the previous day.

Enterprise Products Partners has a lofty 5.7% yield and 27 annual distribution increases behind it. Realty Income has a 5.2% yield backed by 31 years of annual dividend increases.

Medtronic wins FDA's approval for Stealth AXiS in cranial & ENT, expanding its AI-driven surgical platform after spine clearance and boosting growth prospects.

Medtronic (MDT) concluded the recent trading session at $85.74, signifying a -1.61% move from its prior day's close.

Medtronic plc is a stable medical device company currently trading below analyst price targets and undervalued, presenting a potential short-term value opportunity. GLP-1 drugs may not materially threaten MDT; patient discontinuation rates and new surgical eligibility could offset potential cardiovascular equipment demand declines. Revenue and net margin growth are steady, and with product innovation and new market introductions, it is believed to grow at triple the historical rate.

Medtronic said ​on Friday ‌the U.S. Food and ​Drug ​Administration has cleared ⁠its ​surgical system ​for use in cranial and ​ear, ​nose and throat ‌procedures, ⁠expanding the platform beyond ​the ​spine ⁠indication it received ​earlier ​this ⁠year.

GALWAY, Ireland, March 27, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical system for cranial and ear, nose, and throat (ENT) procedures. Cleared for spine procedures in February, the Stealth AXiS™ surgical system unifies surgical planning, navigation, and robotics into a single intelligent system to support surgeons with greater precision and real-time insights during complex procedures.

Medtronic expands its pain portfolio with a new ViaVerte BVNA system deal with Merit, aiming to tap rising demand for minimally invasive chronic pain treatments.